Analyst Ratings for 89bio
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have provided ratings for 89bio (NASDAQ:ETNB), with 2 being bullish and 3 somewhat bullish. There have been no indifferent, somewhat bearish, or bearish ratings. The average price target is now $29.0, down from the previous $32.33, which is still a significant upside from the current price of $7.922. Analysts typically review stocks quarterly and may adjust their predictions based on various financial metrics and company performance.
November 28, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a positive outlook on 89bio with an average price target of $29.0, indicating a potential upside from the current price of $7.922. The recent decrease in the average price target may reflect a tempered but still optimistic view of the stock's future performance.
The unanimous positive ratings from analysts suggest a bullish sentiment towards 89bio, which could lead to increased investor confidence and a potential rise in the stock price in the short term. The reduction in the average price target may slightly temper expectations but still indicates a significant upside potential. Given that analyst ratings can influence market perceptions, especially for small-cap stocks like 89bio, the positive ratings are likely to have a favorable impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100